^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Tri-Ad5

i
Other names: Tri-Ad5, Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Ad5-CEA/Ad5-MUC1/Ad5-Brachyury Vaccine Tri-Ad5, Adenoviral CEA/MUC1/Brachyury Vaccine Tri-Ad5
Associations
Company:
ImmunityBio, National Cancer Institute - Bethesda
Drug class:
Immunostimulant
Related drugs:
Associations
3ms
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (clinicaltrials.gov)
P2, N=186, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2027 --> Feb 2027
Trial completion date
|
MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • EPCAM (Epithelial cell adhesion molecule)
|
Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5
4ms
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (clinicaltrials.gov)
P2, N=186, Recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2027 --> Jul 2027
Trial completion date
|
MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • EPCAM (Epithelial cell adhesion molecule)
|
Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5
10ms
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (clinicaltrials.gov)
P2, N=186, Recruiting, National Cancer Institute (NCI) | Phase classification: P2b --> P2
Phase classification
|
MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • EPCAM (Epithelial cell adhesion molecule)
|
Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5
over1year
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (clinicaltrials.gov)
P2b, N=186, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Aug 2023 --> Mar 2023
Enrollment open • Trial initiation date
|
MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • EPCAM (Epithelial cell adhesion molecule)
|
Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5
over1year
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (clinicaltrials.gov)
P2b, N=186, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2026 --> Feb 2027 | Initiation date: Nov 2022 --> Aug 2023 | Trial primary completion date: Oct 2026 --> Feb 2027
Trial completion date • Trial initiation date • Trial primary completion date
|
MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • EPCAM (Epithelial cell adhesion molecule)
|
Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5